Lithgow Kirstie, Debert Chantel T, Kline Gregory A
Division of Endocrinology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada.
Division of Physical Medicine and Rehabilitation, Department of Clinical Neurosciences Cumming School of Medicine, University of Calgary, Calgary, Canada.
J Rehabil Med Clin Commun. 2018 Nov 16;3:1000008. doi: 10.2340/20030711-1000008. eCollection 2018.
Growth hormone deficiency is a recognized consequence of traumatic brain injury. The aim of this study was to determine adherence to human growth hormone therapy among patients with traumatic brain injury compared with patients with hypothalamic or pituitary disease.
A retrospective chart review of patients with traumatic brain injury referred for growth hormone stimulation testing since December 2013. Within the same electronic medical record, patients who were started on human growth hormone for aetiologies other than traumatic brain injury were reviewed. Adherence to therapy at 1-year followup was compared.
Of the patients with traumatic brain injury, 12/23 (52%) returned for follow-up at 1 year to continue human growth hormone treatment, whereas 11/23 (48%) did not return at 1 year. Amongst the patients with non-traumatic brain injury: 25/29 (86%) continued human growth hormone treatment, vs 4/29 (14%) who did not return. A higher proportion of patients with non-traumatic brain injury continued human growth hormone treatment; x (1, = 52) = 7.238,
There may be differences in the patient-perceived benefits of human growth hormone between these patient populations. However, it is important to consider the potential influences of cognitive and psychosocial dysfunction that can occur in patients with brain injuries.
生长激素缺乏是创伤性脑损伤公认的后果。本研究的目的是确定创伤性脑损伤患者与下丘脑或垂体疾病患者在生长激素治疗方面的依从性。
对自2013年12月以来因生长激素刺激试验而转诊的创伤性脑损伤患者进行回顾性病历审查。在同一电子病历中，对因创伤性脑损伤以外的病因开始使用生长激素的患者进行审查。比较1年随访时的治疗依从性。
创伤性脑损伤患者中，12/23（52%）在1年时返回继续接受生长激素治疗，而11/23（48%）在1年时未返回。在非创伤性脑损伤患者中：25/29（86%）继续接受生长激素治疗，4/29（14%）未返回。非创伤性脑损伤患者中继续接受生长激素治疗的比例更高；x²（1，N = 52）= 7.238。
这些患者群体在生长激素的患者感知益处方面可能存在差异。然而，重要的是要考虑脑损伤患者可能出现的认知和心理社会功能障碍的潜在影响。
